Logo image of BLNE

BEELINE HOLDINGS INC (BLNE) Stock Fundamental Analysis

NASDAQ:BLNE - Nasdaq - US2778025005 - Common Stock - Currency: USD

0.6482  -0.03 (-4.2%)

Premarket: 0.67 +0.02 (+3.36%)

Fundamental Rating

1

Overall BLNE gets a fundamental rating of 1 out of 10. We evaluated BLNE against 33 industry peers in the Beverages industry. Both the profitability and financial health of BLNE have multiple concerns. BLNE is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BLNE had negative earnings in the past year.
BLNE had a negative operating cash flow in the past year.
In the past 5 years BLNE always reported negative net income.
BLNE had a negative operating cash flow in each of the past 5 years.
BLNE Yearly Net Income VS EBIT VS OCF VS FCFBLNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

The Return On Assets of BLNE (-47.82%) is worse than 90.91% of its industry peers.
Industry RankSector Rank
ROA -47.82%
ROE N/A
ROIC N/A
ROA(3y)-44.62%
ROA(5y)-42.41%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BLNE Yearly ROA, ROE, ROICBLNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K

1.3 Margins

BLNE has a Gross Margin of 8.90%. This is amonst the worse of the industry: BLNE underperforms 90.91% of its industry peers.
In the last couple of years the Gross Margin of BLNE has declined.
BLNE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 8.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-26.87%
GM growth 5Y-23.17%
BLNE Yearly Profit, Operating, Gross MarginsBLNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150 -200

More info and screens

0

2. Health

2.1 Basic Checks

BLNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BLNE has more shares outstanding
The number of shares outstanding for BLNE has been increased compared to 5 years ago.
BLNE has a better debt/assets ratio than last year.
BLNE Yearly Shares OutstandingBLNE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50K 100K 150K
BLNE Yearly Total Debt VS Total AssetsBLNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

BLNE has an Altman-Z score of -8.71. This is a bad value and indicates that BLNE is not financially healthy and even has some risk of bankruptcy.
BLNE's Altman-Z score of -8.71 is on the low side compared to the rest of the industry. BLNE is outperformed by 84.85% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.71
ROIC/WACCN/A
WACC7.93%
BLNE Yearly LT Debt VS Equity VS FCFBLNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M

2.3 Liquidity

BLNE has a Current Ratio of 0.29. This is a bad value and indicates that BLNE is not financially healthy enough and could expect problems in meeting its short term obligations.
BLNE's Current ratio of 0.29 is on the low side compared to the rest of the industry. BLNE is outperformed by 87.88% of its industry peers.
A Quick Ratio of 0.18 indicates that BLNE may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.18, BLNE is doing worse than 87.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.29
Quick Ratio 0.18
BLNE Yearly Current Assets VS Current LiabilitesBLNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 86.14% over the past year.
The Revenue for BLNE has decreased by -40.85% in the past year. This is quite bad
BLNE shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.40% yearly.
EPS 1Y (TTM)86.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.88%
Revenue 1Y (TTM)-40.85%
Revenue growth 3Y-9.17%
Revenue growth 5Y11.4%
Sales Q2Q%-74.52%

3.2 Future

The Earnings Per Share is expected to grow by 26.04% on average over the next years. This is a very strong growth
Based on estimates for the next years, BLNE will show a very strong growth in Revenue. The Revenue will grow by 30.21% on average per year.
EPS Next Y95.64%
EPS Next 2Y40.79%
EPS Next 3Y26.04%
EPS Next 5YN/A
Revenue Next Year-0.77%
Revenue Next 2Y31.2%
Revenue Next 3Y30.21%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BLNE Yearly Revenue VS EstimatesBLNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M 25M
BLNE Yearly EPS VS EstimatesBLNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2022 2023 2024 2025 2026 0 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BLNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BLNE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLNE Price Earnings VS Forward Price EarningsBLNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLNE Per share dataBLNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

BLNE's earnings are expected to grow with 26.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.79%
EPS Next 3Y26.04%

More info and screens

0

5. Dividend

5.1 Amount

BLNE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEELINE HOLDINGS INC

NASDAQ:BLNE (6/13/2025, 8:00:02 PM)

Premarket: 0.67 +0.02 (+3.36%)

0.6482

-0.03 (-4.2%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryBeverages
Earnings (Last)05-12 2025-05-12
Earnings (Next)08-12 2025-08-12
Inst Owners3.11%
Inst Owner ChangeN/A
Ins Owners22.13%
Ins Owner Change935.91%
Market Cap5.87M
Analysts82.86
Price TargetN/A
Short Float %3.51%
Short Ratio0.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.54%
Min EPS beat(2)-4.02%
Max EPS beat(2)39.1%
EPS beat(4)1
Avg EPS beat(4)-65.98%
Min EPS beat(4)-247.59%
Max EPS beat(4)39.1%
EPS beat(8)3
Avg EPS beat(8)-64.89%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-64.71%
Min Revenue beat(2)-75.73%
Max Revenue beat(2)-53.69%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.92
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-23.79
EYN/A
EPS(NY)-1.1
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0.71
BVpS-0.27
TBVpS-0.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 8.9%
FCFM N/A
ROA(3y)-44.62%
ROA(5y)-42.41%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-26.87%
GM growth 5Y-23.17%
F-Score3
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.29
Quick Ratio 0.18
Altman-Z -8.71
F-Score3
WACC7.93%
ROIC/WACCN/A
Cap/Depr(3y)66.85%
Cap/Depr(5y)70.3%
Cap/Sales(3y)7.35%
Cap/Sales(5y)8.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.88%
EPS Next Y95.64%
EPS Next 2Y40.79%
EPS Next 3Y26.04%
EPS Next 5YN/A
Revenue 1Y (TTM)-40.85%
Revenue growth 3Y-9.17%
Revenue growth 5Y11.4%
Sales Q2Q%-74.52%
Revenue Next Year-0.77%
Revenue Next 2Y31.2%
Revenue Next 3Y30.21%
Revenue Next 5YN/A
EBIT growth 1Y22.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year52.9%
EBIT Next 3Y46.83%
EBIT Next 5YN/A
FCF growth 1Y69.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.7%
OCF growth 3YN/A
OCF growth 5YN/A